<DOC>
	<DOC>NCT01202071</DOC>
	<brief_summary>The purpose of this study is to compare the pharmacodynamics/pharmacokinetics of 5 mg, 10 mg, 20 mg and 40 mg of Rabeprazole sodium (E3810) when administered repeatedly once daily for 5 days to healthy adult male Japanese participants. This was a single-center, open-label, randomized, four-treatment, four-way crossover study.</brief_summary>
	<brief_title>A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>healthy adult Japanese male between the age of 2040 body mass index between 18.525 clinically significant abnormal physical examination, vital signs or electrocardiogram use of any prescription medication, antacid, nutritional supplement, vitamin preparation, or herbcontaining drug within the previous 4 weeks use of any nonprescription medication within the previous 1 week history of drug or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Rabeprazole</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>healthy adult male Japanese subjects</keyword>
</DOC>